SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-012295
Filing Date
2022-05-04
Accepted
2022-05-04 16:22:58
Documents
59
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20220331.htm   iXBRL 10-Q 1180534
2 EX-31.1 mrtx-2022331xex311.htm EX-31.1 14085
3 EX-31.2 mrtx-2022331xex312.htm EX-31.2 15008
4 EX-32.1 mrtx-2022331xex321.htm EX-32.1 7817
  Complete submission text file 0001628280-22-012295.txt   4987564

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20220331.xsd EX-101.SCH 36605
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20220331_cal.xml EX-101.CAL 46694
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20220331_def.xml EX-101.DEF 143528
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20220331_lab.xml EX-101.LAB 423810
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20220331_pre.xml EX-101.PRE 261169
53 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20220331_htm.xml XML 758598
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 22891847
SIC: 2834 Pharmaceutical Preparations